2016
DOI: 10.3892/etm.2016.3428
|View full text |Cite
|
Sign up to set email alerts
|

Electroacupuncture improves cognitive ability following cerebral ischemia reperfusion injury via CaM-CaMKIV-CREB signaling in the rat hippocampus

Abstract: Abstract. The aim of the present study was to investigate the effect of electroacupuncture (EA) on cognitive deficits, and the underlying mechanism following cerebral ischemia-reperfusion (I/R) via the calmodulin (CaM)-calmodulin-dependent protein kinase type IV (CaMKIV)-cyclic adenosine monophosphate response elements binding protein (CREB) intracellular signaling pathway in the hippocampus. In total, 45 adult female Sprague-Dawley rats were randomly divided into three groups, namely the sham group, the middl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
20
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(22 citation statements)
references
References 40 publications
(40 reference statements)
1
20
0
Order By: Relevance
“…The second paper, a Cochrane review of the efficacy and safety of acupuncture therapy in subacute or chronic ischemic or hemorrhagic stroke, concludes that acupuncture may improve global deficiency and some specific neurological impairments, with no obvious serious adverse sequelae, although most included trials were of limited quality and size [ 66 ]. Still further support is provided by the results and conclusions of four preclinical studies published in 2016, all of which demonstrate that EA improves neurological function after cerebral ischemia/reperfusion injury in rats [ 67 , 68 , 69 , 70 ].…”
Section: Discussionmentioning
confidence: 93%
“…The second paper, a Cochrane review of the efficacy and safety of acupuncture therapy in subacute or chronic ischemic or hemorrhagic stroke, concludes that acupuncture may improve global deficiency and some specific neurological impairments, with no obvious serious adverse sequelae, although most included trials were of limited quality and size [ 66 ]. Still further support is provided by the results and conclusions of four preclinical studies published in 2016, all of which demonstrate that EA improves neurological function after cerebral ischemia/reperfusion injury in rats [ 67 , 68 , 69 , 70 ].…”
Section: Discussionmentioning
confidence: 93%
“…Numerous basic experimental studies have shown that EA can improve the learning and memory abilities of rats with cerebral ischemia. 26 28 EA treatment can enhance the expression of endogenous BDNF, thereby improving the environment to enhance survival of intracerebral neurons and inhibiting hippocampal cell apoptosis. 29 EA treatment can improve brain NGF availability and action, 30 EA stimulation can upregulate cerebral NGF expression in cerebral ischemia rats.…”
Section: Discussionmentioning
confidence: 99%
“…Approximately 15 μg of protein was loaded into NuPAGE 4–12% Bis-Tris protein gels (ThermoFisher, cat# NP0321BOX), separated with 200 V for approximately 1 h, and electrotransferred to PVDF membrane in the XCell II Blot Module for wet (tank) transfer (ThermoFisher) for 90 min at 30 V. The membrane was blocked in 5% non-fat dry milk in TBS buffer, pH 7.4 (Quality Biological, cat# 351-086-101) plus 0.1% Tween 20 (Sigma-Aldrich) for 1 h at room temperature and then exposed to primary antibodies. Antibodies for detection of NEUROD1, CALB1, and CAMKIV were purchased from Cell Signaling: NeuroD (D90G12) rabbit mAb: cat# 7019, 1:1,000 dilution (for WB validation, see https://www.cellsignal.com/products/primary-antibodies/neurod-d90g12-rabbit-mab/7019); Calbindin (D1I4Q) XP rabbit mAb: cat# 13176, 1:1,500 dilution (for WB validation and references, see https://www.cellsignal.com/products/primary-antibodies/calbindin-d1i4q-xp-rabbit-mab/13176?_=1487290902164&Ntt=13176&tahead=true) 8082 ; CaMK IV: rabbit, cat# 4032, 1:1,000 dilution (for WB validation and references, see https://www.cellsignal.com/products/primary-antibodies/camkiv-antibody/4032; Product Citations) 83,84 . Equal loading was verified by western blotting of actin (α-actin: 1:10,000, mouse, Sigma-Aldrich, clone AC-15, cat# A5441; for WB validation see http://www.sigmaaldrich.com/catalog/product/sigma/a5441?lang=en&region=US).…”
Section: Methodsmentioning
confidence: 99%